| pubmed-article:12415196 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:12415196 | lifeskim:mentions | umls-concept:C0278480 | lld:lifeskim |
| pubmed-article:12415196 | lifeskim:mentions | umls-concept:C0016360 | lld:lifeskim |
| pubmed-article:12415196 | lifeskim:mentions | umls-concept:C0023413 | lld:lifeskim |
| pubmed-article:12415196 | lifeskim:mentions | umls-concept:C0023556 | lld:lifeskim |
| pubmed-article:12415196 | lifeskim:mentions | umls-concept:C0085533 | lld:lifeskim |
| pubmed-article:12415196 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:12415196 | pubmed:dateCreated | 2002-11-4 | lld:pubmed |
| pubmed-article:12415196 | pubmed:abstractText | Adjuvant chemotherapy for colon cancer has been established during the past decade. From 1990 until recently treatment with 5- fluorouracil (5-FU) and levamisole (LEV) lasting 12 months was recommended as standard treatment. At the initiation of this study in 1993 improvement of adjuvant therapy was expected by the modulation of 5-FU with folinic acid (FA). Therefore, we decided to perform a prospective randomized multicenter trial to compare standard 5-FU/LEV to 5-FU/FA for either 6 or 12 months. | lld:pubmed |
| pubmed-article:12415196 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12415196 | pubmed:language | eng | lld:pubmed |
| pubmed-article:12415196 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12415196 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:12415196 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12415196 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12415196 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:12415196 | pubmed:month | Oct | lld:pubmed |
| pubmed-article:12415196 | pubmed:issn | 0378-584X | lld:pubmed |
| pubmed-article:12415196 | pubmed:author | pubmed-author:FritzeDD | lld:pubmed |
| pubmed-article:12415196 | pubmed:author | pubmed-author:QueisserWW | lld:pubmed |
| pubmed-article:12415196 | pubmed:author | pubmed-author:SturmJJ | lld:pubmed |
| pubmed-article:12415196 | pubmed:author | pubmed-author:LindemannHH | lld:pubmed |
| pubmed-article:12415196 | pubmed:author | pubmed-author:HartungGG | lld:pubmed |
| pubmed-article:12415196 | pubmed:author | pubmed-author:HagmüllerEE | lld:pubmed |
| pubmed-article:12415196 | pubmed:author | pubmed-author:Kopp-Schneide... | lld:pubmed |
| pubmed-article:12415196 | pubmed:author | pubmed-author:WojatschekCC | lld:pubmed |
| pubmed-article:12415196 | pubmed:author | pubmed-author:DencausseYY | lld:pubmed |
| pubmed-article:12415196 | pubmed:copyrightInfo | Copyright 2002 S. Karger GmbH, Freiburg | lld:pubmed |
| pubmed-article:12415196 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:12415196 | pubmed:volume | 25 | lld:pubmed |
| pubmed-article:12415196 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:12415196 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:12415196 | pubmed:pagination | 426-30 | lld:pubmed |
| pubmed-article:12415196 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:12415196 | pubmed:meshHeading | pubmed-meshheading:12415196... | lld:pubmed |
| pubmed-article:12415196 | pubmed:meshHeading | pubmed-meshheading:12415196... | lld:pubmed |
| pubmed-article:12415196 | pubmed:meshHeading | pubmed-meshheading:12415196... | lld:pubmed |
| pubmed-article:12415196 | pubmed:meshHeading | pubmed-meshheading:12415196... | lld:pubmed |
| pubmed-article:12415196 | pubmed:meshHeading | pubmed-meshheading:12415196... | lld:pubmed |
| pubmed-article:12415196 | pubmed:meshHeading | pubmed-meshheading:12415196... | lld:pubmed |
| pubmed-article:12415196 | pubmed:meshHeading | pubmed-meshheading:12415196... | lld:pubmed |
| pubmed-article:12415196 | pubmed:meshHeading | pubmed-meshheading:12415196... | lld:pubmed |
| pubmed-article:12415196 | pubmed:meshHeading | pubmed-meshheading:12415196... | lld:pubmed |
| pubmed-article:12415196 | pubmed:meshHeading | pubmed-meshheading:12415196... | lld:pubmed |
| pubmed-article:12415196 | pubmed:meshHeading | pubmed-meshheading:12415196... | lld:pubmed |
| pubmed-article:12415196 | pubmed:meshHeading | pubmed-meshheading:12415196... | lld:pubmed |
| pubmed-article:12415196 | pubmed:meshHeading | pubmed-meshheading:12415196... | lld:pubmed |
| pubmed-article:12415196 | pubmed:meshHeading | pubmed-meshheading:12415196... | lld:pubmed |
| pubmed-article:12415196 | pubmed:year | 2002 | lld:pubmed |
| pubmed-article:12415196 | pubmed:articleTitle | Adjuvant chemotherapy in stage III colon cancer with 5-fluorouracil and levamisole versus 5-fluorouracil and leucovorin. | lld:pubmed |
| pubmed-article:12415196 | pubmed:affiliation | Onkologisches Zentrum, III Medizinische Klinik, Universitätsklinikum Mannheim, Germany. denc@gmx.net | lld:pubmed |
| pubmed-article:12415196 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:12415196 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:12415196 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:12415196 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:12415196 | pubmed:publicationType | Multicenter Study | lld:pubmed |
| pubmed-article:12415196 | pubmed:publicationType | Clinical Trial, Phase III | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12415196 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12415196 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12415196 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12415196 | lld:pubmed |
